The takeaway from this timeline is that there are a lot of dates from various legislative frameworks and that public statements on when a Janumet generic could be available in the U.S. have differed between sources throughout 2026. Any individual who receives a particular date for the broad availability of the US Janumet generic should be cautious about that date, given current developments.

FDA Approval vs Commercial Availability: The Distinction That Matters

This is the most misunderstood part of the Janumet generic debate. There’s a difference between the FDA approving a generic pharmaceutical and seeing it on the shelves of your neighborhood drugstore.

When a generic version of Janumet is submitted to the FDA as an ANDA (Abbreviated New Drug Application), the FDA evaluates whether it is bioequivalent to the brand-name drug. The FDA approval means that the generic meets the necessary standards. The goods does not necessarily ship to pharmacies the next day.

Brand manufacturers and generic challengers often settle with terms that include certain delayed entry dates, so a generic company may have an FDA-approved Janumet generic that is contractually prevented from launch until the specified date, even though it has received formal approval to launch. This is standard practice in pharmaceutical patent disputes and is the reason some medicine availability databases show a generic as approved, yet patients cannot get it in pharmacies.

If you’ve seen a source that said a generic version of Janumet was FDA-approved and thought it was available right now, this settlement-induced gap is probably why it’s not yet available in your area.

The Zituvimet Confusion

There’s a different branded medicine called Zituvimet, which is a different brand owned by a different company, but has the same drug combination of sitagliptin and metformin, in fixed doses, as Janumet. This is one of the major sources of confusion in the Janumet generic search results.

According to the latest drug supply surveillance, Zituvimet already has generic versions that are approved by the FDA and sold on the market. This means that a person searching for the generic of Janumet may find search results that describe an approved and available sitagliptin/metformin generic, and mistakenly believe that this is about Janumet itself, when in fact it is about the Zituvimet product line.

In make-up, the active ingredients are the same. Janumet and Zituvimet are not the same in terms of regulatory status and brand ownership. So, it would be a mistake to assume that a Janumet generic is available in the US based on a generic search result for Zituvimet.

Why Metformin Being Generic Does Not Mean Janumet Is

Metformin has been off-patent and widely available as a generic drug for decades, provided as an inexpensive single pill at almost every pharmacy. This can lead to the assumption that since metformin is a generic drug, the combination drug containing it should be easily available as a generic.

This is not how the fixed-dose combo patents work. The combo medication ( and notably the newer half, which is sitagliptin here ) might have its own exclusivity even if one ingredient has been generic for a long time. This is a common pattern in many fixed-dose combination therapies for diabetes and cardiovascular diseases, where a well-established generic drug is combined with a new patented drug, allowing the combination product to be protected for exclusivity associated with the new component, regardless of the status of the older drug.

What Janumet Generic Actually Costs When Available

Industry examinations of comparable diabetic medicine patent expirations generally find that generics tend to be 80 to 85% less expensive than their branded equivalents when a real Janumet generic is introduced broadly in the US market, after many manufacturers engage in price competition. Typically, the price decrease does not occur immediately on the same date of the first generic launch but rather tends to increase in the months after the launch as other manufacturers enter the market and multi-source competition increases.

This is a pattern that has been seen in the past with other blockbuster combination drugs when patents are close to expiry, and this is the main reason for the increased interest in the Janumet generic timeline. The difference between the price of the brand and the price of multi-source generics that come later is significant over a year of use for a chronic daily medication.

The International Generic Alternative Available Now

It’s the practical approach for those who want a generic Janumet today and don’t want to wait until the US settlement timeline is fully ironed out.

The sitagliptin and metformin combination pills are made worldwide by WHO-GMP-certified pharmaceutical manufacturers, under a regulatory framework different from the US FDA ANDA process, but nevertheless meeting their own rigorous manufacturing and quality standards. These products are acquired from international markets and are not bound by the same Merck settlement timeline that governs domestic generic entry in the US, as they are created and controlled outside of that particular US patent and litigation framework.

This is a genuine generic option for Janumet, regardless of the FDA ANDA process discussed above, and it is the alternative that does not have to wait for the patent to expire in November 2026 or the uncertain launch dates based on settlements for resolution. The active ingredients are the same compounds, sitagliptin and metformin. The difference is in the regulatory and manufacturing processes, not in the medicine itself.

rxfarmacia.com carries Sitagliptin & Metformin (Janumet 50mg/500mg) sourced from a verified international manufacturer under this pathway. View the product page at RxFarmacia.com for current availability and dosing options.

What to Do If You Cannot Access Janumet Right Now

• Check out some of the nearby pharmacies. Janumet is made only by Merck under its brand name; thus, any disruption in Merck’s supply chain might lead to localized shortages, even though it is not officially listed as an FDA drug shortage.
• Ask your doctor about other fixed-dose combinations, such as Jentadueto (linagliptin/metformin), which may be more readily available and may not require the same renal dose adjustments in some cases.
• Ask whether the use of sitagliptin and metformin as separate pills, rather than the fixed-dose combination, is a feasible interim option, as metformin alone is readily available as a generic.
• If the availability of the Janumet brand remains a hurdle to treatment adherence, inquire about the internationally sourced sitagliptin/metformin option with your physician.

Frequently Asked Questions

Is there a generic for Janumet?

As of mid-2026, a broadly available US-market generic of the brand-name Janumet had not been launched, although regulatory preparations were moving ahead. The primary patent for sitagliptin is due to expire on November 24, 2026; however, settlement agreements indicate that generic versions might be available in the middle to late 2026. However, FDA approval of a generic ANDA for Janumet does not ensure immediate commercial availability because of the provisions of delayed entry provided for in the settlements. Currently, generic versions of sitagliptin/metformin are produced in other countries and can be purchased from approved international pharmacies, regardless of the US patent timeline.

When will Janumet generic be available?

Public disclosures on the actual launch date of the Janumet generic in the United States have varied widely, with some sources suggesting mid-2026, depending on Merck’s litigation settlement terms and the expiration of the main sitagliptin patent on Nov. 24, 2026. Many manufacturers with FDA-approved ANDAs are expected to enter the market once the delayed entry restrictions, based on the settlement, are lifted. Different sources do not consistently report the exact date when consumers will be able to purchase a generic version of Janumet at pharmacies nationwide.

What is the generic name for Janumet?

Janumet is the brand name for a fixed-dose combination of the two active ingredients sitagliptin and metformin hydrochloride. Sitagliptin (DPP-4 inhibitor) and metformin (biguanide) are combined and marketed under the brand name Janumet.

Is Zituvimet the same as Janumet generic?

Zituvimet is a different brand name drug containing the same active ingredients combination of sitagliptin and metformin; however, it is not the generic of Janumet. Zituvimet is FDA-authorized, but its generic counterparts aren’t, which can sometimes cause confusion when people are searching for Janumet generics and see results for Zituvimet instead.

Why is metformin generic but Janumet is not?

Metformin has been a generic medicine for decades now, once the patent expired. Janumet is a fixed-dose combination of metformin and sitagliptin, a new drug with exclusivity based on patent and settlement. The availability of the combination product as a generic depends on the patent status of the new component, not the previous, already-generic one.

How much cheaper is Janumet generic expected to be?

Following conventional patterns of patent expiry for comparable diabetes therapies, when there is a large number of producers, generic medications are usually 80 to 85% cheaper than their branded counterparts. In general, the rate of decline accelerates in the months after the first generic’s entry, as more manufacturers enter the market and multi-source competition intensifies, rather than falling to its lowest point on day one.

The Bottom Line

The generic version of Janumet is in the process of a transition as of mid-2026, and the truthful answer calls for more depth than most sources provide. The brand name Janumet is now protected by patent and settlement agreements in the United States, with a key patent expected to expire on November 24, 2026, and settlement terms pointing to a wider generic launch in mid to late 2026. Just because a generic Janumet ANDA has been approved by the FDA doesn’t mean it will be on pharmacy shelves anytime soon. The unique name-branding of the Zituvimet product also adds a lot of ambiguity in search results on the subject.

No matter when the domestic patent issue is resolved, if you need sitagliptin and metformin immediately, you can obtain combo tablets manufactured outside the U.S. by WHO-GMP-certified manufacturers as a legitimate generic substitute for Janumet.